CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

Three Lakes Foundation and the American College of Chest Physicians (CHEST) recently announced their collaboration on a multiphase educational initiative aiming to reduce the time it takes to diagnose patients with Interstitial Lung Diseases (ILD). Affecting around 400,000 people in the United States, ILDs are a group of diseases that cause lung inflammation and/or permanent scars (fibrosis). The symptoms are […]

Continue reading »

Cough-Specific QOL Linked to Poor Outcomes in ILD Patients

Poor cough-specific quality of life (QOL) was independently associated with respiratory hospitalization, death, and lung transplantation in a large population of well-characterized patients with interstitial lung disease (ILD), new research shows. “Unfortunately, chronic cough in ILD is a pervasive and very distressing problem for our patients,” Janet Lee, MD, University of Utah, Salt Lake City, Utah, told Medscape Medical News […]

Continue reading »

Parathyroidectomy no better for mild primary hyperparathyroidism

For patients with mild primary hyperparathyroidism (PHPT), outcomes at 10 years do not differ for parathyroidectomy (PTX) compared with observation without intervention (OBS), according to a study published online April 19 in the Annals of Internal Medicine. Mikkel Pretorius, M.D., from Oslo University Hospital in Norway, and colleagues examined the effect of PTX on mild PHPT with regard to mortality […]

Continue reading »

Coway Airmega 250 review

In this Coway Airmega 250 review, we’ll explain everything you need to know about this high-end air purifier, including how its three levels of filtration work, how quickly it absorbs particles, its design, and how easy it is to disassemble and clean. Because the Coway Airmega 250 is quite expensive in terms of air purifiers (retailing from around $300-$400), it’s […]

Continue reading »

Advanced cancer: Two drugs show promise in early clinical trials

Researchers have found two drugs to be safe and effective in treating individuals with advanced solid tumors. These medications, ATR inhibitor elimusertib and PARP inhibitor AZD5305, can block key mediators behind DNA damage response (DDR). In clinical studies, these drugs only induced “reversible and manageable” adverse side effects in some participants. An estimated 1.9 million new cancer cases are expected […]

Continue reading »

All cells are important: A roadmap to characterize lymphoma stroma

Lymphomas are blood cancers that often start from lymph nodes. Lymph nodes contain not only hematopoietic cells, mainly B- and T-lymphoid cells, but also non-hematopoietic cells (NHCs), also called stromal cells. We know from previous research that NHCs have an active role in the development of lymphomas. However, it is still not clear how they promote the expansion and proliferation […]

Continue reading »

Vijoice granted first approval for treatment of PROS

Vijoice (alpelisib) has been granted accelerated approval for severe PIK3CA-related overgrowth spectrum (PROS), the U.S. Food and Drug Administration announced April 6. Vijoice, the first treatment to be FDA-approved for PROS, is indicated for patients aged 2 years or older with severe manifestations of PROS at a dose of 50 mg and 250 mg taken orally once daily with food […]

Continue reading »
1 479 480 481 482 483 1,322